Sequencing data was deposited in the Gene Expression Omnibus database (<https://www.ncbi.nlm.nih.gov/geo/>; GEO \# GSE130704).

Introduction {#sec004}
============

Understanding the mechanisms underlying cardiac failure in the context of cancer has the potential to reduce morbidity and chemotherapy-associated cardiac toxicity. Humans with cachexia associated with lung, pancreatic and gastrointestinal cancers not only demonstrate skeletal muscle wasting, but also manifest cardiac atrophy and reduced cardiac function\[[@pone.0226440.ref001]--[@pone.0226440.ref010]\]. Cramer et al. showed that patients with colorectal cancer had reduced left ventricular (LV) ejection fraction, peak oxygen consumption, and higher levels of the endothelium-derived C-terminal-pro-endothelin-1, independent of chemotherapy\[[@pone.0226440.ref002]\]. Pavo et al. found elevated serum concentrations of NT-proBNP, MR-proANP, MR-proADM, CT-pro-ET-1 and hsTnT in an unselected population of patients with cancer prior to induction of cardiotoxic anticancer therapy. The biomarkers and copeptin were related to all-cause mortality, suggesting the presence of myocardial damage is directly linked to disease progression. Chemotherapy results in additional cardiac dysfunction and heart failure in some cancer patients\[[@pone.0226440.ref011], [@pone.0226440.ref012]\]. There is a need to understand the mechanisms of cardiac dysfunction in the context of chemotherapy-naive cancer patients in order to develop therapies that can mitigate cancer associated heart failure and identify those at increased risk of chemotherapy-induced heart failure.

Pre-clinical studies where tumor cells are administered to rodents have been developed to define the effects of tumor cells on cardiac function\[[@pone.0226440.ref003]\]. In AH-130 hepatoma Wistar-Han rats, loss of body weight in tumor-bearing rats is accompanied by a reduction in heart weight, LV mass and contractility, increased fibrosis, decreased calcium-dependent ATPase activity, and altered heart muscle redox balance\[[@pone.0226440.ref013]--[@pone.0226440.ref015]\]. Wistar-Han rats injected with Walker-256 tumor cells also present with cardiac failure\[[@pone.0226440.ref016]\]. Further, cardiac fractional shortening and cardiac wall thickness were significantly reduced in male CD2F1 mice administered colon-26 adenocarcinoma cells compared to control mice\[[@pone.0226440.ref017]\]. Tumor-bearing mice also exhibited increased cardiac fibrosis, decreased cardiac myofibrillar proteins, increased protein ubiquitination, and altered composition of MHC. Increased expression of brain natriuretic peptide, c-Fos and decreased peroxisome proliferator-activated receptor α and its responsive gene carnitine palmitoyltransferase 1 are noted in tumor-bearing mice\[[@pone.0226440.ref017], [@pone.0226440.ref018]\]. The expression of biomarkers of protein degradation is increased in the hearts of female CD2F1 mice with systolic and diastolic dysfunction induced by colon-26 tumor cells\[[@pone.0226440.ref019]\]. Others have found heart failure, decreased cardiac cell size, increased autophagy and normal caspase 3 activity and protein ubiquitination in male (but not female) CD2F1 (Balb/c X DBA2) mice injected with colon-26 adenocarcinoma cells\[[@pone.0226440.ref018], [@pone.0226440.ref020], [@pone.0226440.ref021]\]. In sum, animal models demonstrate reduced cardiac function, increased cardiac fibrosis with variable evidence for altered protein ubiquitination. There is very limited information describing changes in protein synthesis, mitochondrial function, and RNA expression.

In a mouse model of lung cancer cell-associated cachexia, we now describe novel mechanisms that are associated with cardiac atrophy and impaired function. We show that cardiac protein synthesis is markedly reduced in the absence of overt evidence for increased protein degradation. We demonstrate morphological and biochemical alterations in cardiac mitochondria in tumor-bearing mice and attenuated mitochondrial oxygen uptake in cultured human cardiomyocytes exposed to conditioned media from tumor cells. Marked reduction in the mRNA expression of apelin and the apelin receptor were evident in hearts of tumor-bearing mice. The described model of lung cancer cell-induced cardiac cachexia is likely to be useful in the isolation of factors causing reduced cardiac function in the context of cancer, and may open the door to therapies designed to reduce cardiac failure in patients with cancer.

Materials and methods {#sec005}
=====================

Ethics statement {#sec006}
----------------

The Mayo Clinic Animal Care and Use Committee specifically approved animal experiments conducted in this study: Mayo Clinic IACUC protocol number A00002917-17.

Cardiomyocyte and LLC1 tumor cell culture {#sec007}
-----------------------------------------

Lewis lung carcinoma (LLC1) cells (American Type Culture Collection) were grown in Dulbecco's Modified Eagle's Medium (DMEM) with 10% fetal bovine serum (FBS). AC16 human cardiomyocytes (Millipore Sigma) were grown in DMEM/F12 with 12.5% FBS. Cells were grown at 37° C with 5% CO~2~. Conditioned medium (CM) from LLC1 cells grown for 24h was filtered and diluted to 25% in fresh media prior to treatment of AC16 cardiomyocytes.

Animal use {#sec008}
----------

Experiments were approved by the Mayo Clinic Institutional Animal Care and Use Committee. Seven week-old C57BL/J6 male and female mice were obtained from the Jackson Laboratory and maintained on PicoLab^®^ 5053 rodent diet. 0.1 mL of PBS or 1 x 10^6^ LLC1 tumor cells in PBS were injected subcutaneously into the left flank of 7 week-old mice. Body mass was recorded prior to and 14 days post-injection. At 14 days, the animals were euthanized with carbon dioxide and tissues were isolated, weighed and stored at -80° C.

Echocardiography {#sec009}
----------------

14 days post vehicle- or LLC1 tumor-injected mice were anesthetized with isoflurane (1.5% v/v in O~2~) before echocardiography\[[@pone.0226440.ref022], [@pone.0226440.ref023]\]. A Vivid 7 Ultrasound Unit (GE Medical Systems) was used for the echocardiography\[[@pone.0226440.ref022], [@pone.0226440.ref023]\]. All the measurements and calculations were performed according to the American Society of Echocardiography guidelines. EchoPAC software (GE) was used for data analysis.

Fractional protein synthesis rates {#sec010}
----------------------------------

Mice were injected intraperitoneally with 1.5 mmoles/kg ^13^C~6~-phenylalanine (Cambridge Isotope Laboratories, 99 atom percent excess) 25 mins prior to euthanasia and collection of heart tissue\[[@pone.0226440.ref024]\]. Cardiac ventricular tissue was isolated and frozen in liquid nitrogen. 20 mg of pulverized heart tissue was suspended in 5% sulfosalicylic acid and sonicated for 10 mins at 4° C to extract the tissue fluid (TFF) free amino acids. The tissue pellets were washed with petroleum ether and heated to 60° C for 90 mins in 0.8 M NaOH. Tissue supernatants obtained after NaOH treatments were hydrolyzed at 110° C for 20h in 3N hydrochloric acid. The hydrolysates and TFF samples were purified on cation exchange columns (BioRad, AG 50W-X8 resin) and dried. The TFF and hydrolysate amino acids were analyzed via mass spectrometry as described previously\[[@pone.0226440.ref025]\]. The fractional synthesis rates (FSR) of cardiac muscle protein were calculated from isotopic enrichment of ^13^C~6~ phenylalanine in tissue (Ie), using the TFF phenylalanine enrichment (Pe) as the precursor pool\[[@pone.0226440.ref024]\] and the equation: FSR (%/h) = \[Ie/(Pe \* t)\] \* 100, where t represents time\[[@pone.0226440.ref026]\].

Cardiac RNA isolation and mRNA sequencing {#sec011}
-----------------------------------------

Ventricular tissue was suspended in Qiazol® Lysis Reagent (Qiagen) and homogenized. Total RNA purification was performed using a miRNeasy® Mini Kit (Qiagen) and quantified via Nanodrop^™^ ND-1000 spectrophotometry. 200 ng of RNA/sample were submitted to Mayo's Gene Expression Core for Illumina library preparation (RNA sample kit, v2) and sequencing (150 base paired ends index reads, Illumina HiSeq4000 platform) as previously described\[[@pone.0226440.ref027], [@pone.0226440.ref028]\]. Mouse genome build (mm10) was used in sequencing read alignment. Sequencing data was deposited in the Gene Expression Omnibus database (<https://www.ncbi.nlm.nih.gov/geo/>; GEO \# GSE130704).

Analysis of mRNA sequencing data {#sec012}
--------------------------------

mRNA-seq data was processed by the Bioinformatics Core to identify mRNAs that were differentially expressed between the PBS-injected and LLC1 tumor cell-injected groups as previously described\[[@pone.0226440.ref027], [@pone.0226440.ref028]\].

Transmission electron microscopy of cardiac mitochondria {#sec013}
--------------------------------------------------------

Ventricular samples were stored in Trump's fixative (4% paraformaldehyde, 1% glutaraldehyde, 100 mM cacodylic acid, 2 mM MgCl~2~) at 4°C. The Mayo Electron Microscopy Core processed the samples for osmium tetraoxide staining, resin embedding and ultrathin-sectioning for transmission electron microscopy (TEM)\[[@pone.0226440.ref028]\] with a JEOL JEM-140 microscope with an accelerating voltage of 80 kV. Longitudinal section images were collected at random with a fixed magnification of 20,000. Three samples from tumor-bearing and three samples from control mice were processed for TEM. Three images of each sample were analyzed. Mitochondria were traced using ImageJ software to provide cross-sectional area, aspect ratio and form factor data\[[@pone.0226440.ref029], [@pone.0226440.ref030]\].

AC16 cardiomyocyte oxygen consumption rates {#sec014}
-------------------------------------------

Mitochondrial oxygen consumption was measured with a Seahorse XF24 Analyzer (Agilent Technologies) as previously described\[[@pone.0226440.ref031]\]. AC16 cells were grown to confluency and treated for 24h with either 25% (v/v) LLC1 CM or 25% non-CM. Oxygen consumption rates were measured following sequential addition of 1 μM oligomycin, 1 μM FCCP and 0.5 μM rotenone + antimycin A and normalized to protein.

Immunoblot analysis {#sec015}
-------------------

Cardiac muscle homogenates were prepared by snap freezing samples in liquid nitrogen, followed by pulverization and suspension of the powder in T-PER (Thermo). Sodium dodecyl sulfate polyacrylamide gel electrophoresis of cardiac tissue homogenates was performed using NuPage 4--12% gradient gels (Invitrogen) with loading of 2 μg protein per lane. Following electrophoresis, proteins were transferred to polyvinylidene fluoride membranes, followed by treatment with antibodies directed against components of mitochondrial OXPHOS complexes (abcam, ab 110413) and developed using a chemiluminescent reagent kit (Roche). Corrections for protein loading were performed using SYPRO Ruby (Thermo). The density of various protein bands was quantitative using Image J (NIH).

Histological assessment of fibrosis in cardiac tissue sections {#sec016}
--------------------------------------------------------------

Cardiac tissues derived from tumor-bearing mice or vehicle-injected mice were embedded in paraffin, fixed, sectioned and stained with hematoxylin-eosin or Masson trichrome stain. Sections were assessed by a pathologist for the presence or absence of fibrosis.

Statistical methods {#sec017}
-------------------

Statistical differences between vehicle- and LLC1 tumor-bearing conditions were analyzed using Student's two-tailed t test, assuming equal variance. A p value of \< 0.05 was regarded as statistically significant. A cut-off for the false discovery rate was set at 0.05 to determine significant changes in mRNA expression.

Results {#sec018}
=======

Echocardiography reveals impaired heart function in male but not female LLC1 tumor-bearing mice {#sec019}
-----------------------------------------------------------------------------------------------

14 days post LLC1 tumor cell or PBS vehicle injection, heart echocardiography showed that tumor-bearing male mice had significantly thinner LV posterior walls (LVPW, 0.628 ± 0.04 mm systole and 0.482 ± 0.03 mm diastole) compared to vehicle-injected mice (1.122 ± 0.04 mm systole and 0.698 ± 0.01 mm diastole; both p \< 0.0001, [Fig 1A and 1B](#pone.0226440.g001){ref-type="fig"}). The interventricular septa (IVS) of the tumor-bearing male mice in systole were also significantly thinner, 0.833 ± 0.04 mm compared to 1.099 ± 0.02 mm in the vehicle-injected mice (p \< 0.0001, [Fig 1C](#pone.0226440.g001){ref-type="fig"}). The IVS in diastole was not significantly different between the two groups (p = 0.29, [Fig 1D](#pone.0226440.g001){ref-type="fig"}). The LV internal dimensions (LVID) of the tumor-bearing males were significantly increased, 3.303 ± 0.08 mm systole and 4.113 ± 0.04 mm diastole, compared to 2.607 ± 0.08 mm systole and 3.699 ± 0.11 mm diastole in vehicle-injected mice (p \< 0.0001 and p = 0.0035, [Fig 1E and 1F](#pone.0226440.g001){ref-type="fig"}). Heart ejection fraction (EF) was significantly impaired in tumor-bearing male mice, 46.56 ± 2.5 (Teichholz) and 48.22 ± 2.5% (Cubed) versus 63.4 ± 1.1 (Teichholz) and 65.1 ± 1.1% (Cubed) in vehicle-injected male mice (both p \< 0.0001, [Fig 1G and 1H](#pone.0226440.g001){ref-type="fig"}). The percent fractional shortening (% FS) was significantly impaired in tumor-bearing male mice, 19.67 ± 1.3% compared to 29.4 ± 0.8% in vehicle-injected male mice (p \< 0.0001, [Fig 1I](#pone.0226440.g001){ref-type="fig"}).

![Effects of PBS- and LLC1 tumor cell-injection on ventricular echocardiography in male mice 14 days post-injection of vehicle or cells.\
A. LV posterior wall (LVPW) thickness in systole. B. LVPW thickness in diastole. C. Interventricular septum (IVS) thickness in systole. D. IVS thickness in diastole. E. LV internal dimension (LVID) in systole. F. LVID in diastole. G. Ejection fraction (%) calculated by the Teichholz method. H. Ejection fraction (%) calculated by the cubed method. I. Percentage (%) fractional shortening.](pone.0226440.g001){#pone.0226440.g001}

Female mice injected with tumor cells displayed no differences on echocardiography compared with PBS-injected mice ([Fig 2](#pone.0226440.g002){ref-type="fig"}, panels A-I).

![Echocardiography in PBS- and LLC1 cell-injected female mice.\
A. LVPW thickness in systole. B. LVPW thickness in diastole. C. IVS thickness in systole. D. IVS thickness in diastole. E. LVID in systole. F. LVID in diastole. G. Ejection fraction (%) calculated by the Teichholz method. H. Ejection fraction (%) calculated by the cubed method. I. Percentage (%) fractional shortening.](pone.0226440.g002){#pone.0226440.g002}

Cardiac fractional protein synthesis rate is decreased in male tumor-bearing mice {#sec020}
---------------------------------------------------------------------------------

We investigated whether decreased protein synthesis might be contributing to the cardiac atrophy in LLC1 tumor-bearing male mice. Cardiac ventricular samples were analyzed to assess incorporation of labeled ^13^C~6~-phenylalanine into protein\[[@pone.0226440.ref026]\]. The fractional protein synthesis rate was significantly decreased in tumor-bearing male mice compared to PBS-injected mice (FSR 0.386 ± 0.02%/h in tumor-bearing mice versus 0.492 ± 0.03%/h in vehicle-injected mice (p = 0.025, [Fig 3A](#pone.0226440.g003){ref-type="fig"})). These data are consistent with the measured cardiac mass in tumor bearing and control mice. Fourteen days following the injection of tumor cells or vehicle, heart masses tended to be lower in tumor-bearing male mice (110.7 ± 3.3 g in tumor-bearing mice compared to 121.9 ± 5.4 g in vehicle-injected mice, p = 0.10, [Fig 3B](#pone.0226440.g003){ref-type="fig"}). Tumor-bearing male mice had heart/body mass ratios of 0.0047 ± 0.0001 compared to 0.0052 ± 0.0002 in the vehicle-injected group (p = 0.10, [Fig 3C](#pone.0226440.g003){ref-type="fig"}). In female mice the heart masses were similar in PBS-injected and tumor-bearing groups (93.3 ± 2.5 g and 96.1 ± 1.9 g, respectively (p = 0.38)).

![A. Protein fractional synthesis rates in the hearts of tumor-bearing and control mice. B. Heart masses of tumor-bearing and control mice. C. Heart/body mass ratios of tumor-bearing and control mice.](pone.0226440.g003){#pone.0226440.g003}

Altered morphology of cardiac mitochondria of male LLC1 tumor-bearing mice {#sec021}
--------------------------------------------------------------------------

Mitochondria play a major role in the generation of energy in cardiac tissue\[[@pone.0226440.ref032]\]. We assessed changes in mitochondrial morphology using transmission electron microscopy of cardiac muscle from tumor-bearing mice and controls. Cardiac intra-myofibrillar mitochondria from the tumor-bearing mice appeared altered in appearance ([Fig 4A](#pone.0226440.g004){ref-type="fig"}) compared to cardiac mitochondria of control mice. The ventricular mitochondrial cross-sectional area was 0.3889 ± 0.028 μm^2^ in tumor-bearing mice compared to 0.4821 ± 0.042 in the PBS-injected group (p = 0.084, [Fig 4B](#pone.0226440.g004){ref-type="fig"}). Cardiac mitochondrial number in tumor-bearing mice was 31.22 ± 2.6 mitochondria/image compared to 26.56 ± 1.9 in the PBS group (p = 0.17, [Fig 4C](#pone.0226440.g004){ref-type="fig"}). Mitochondrial density was statistically similar between the groups ([Fig 4D](#pone.0226440.g004){ref-type="fig"}). Cardiac mitochondrial aspect ratio (AR, major/minor axis) was increased in tumor-bearing mice, 1.764 ± 0.05 compared to 1.636 ± 0.03 in the vehicle-injected group, p = 0.042, revealing that cardiac mitochondria have a more elongated shape in tumor-bearing mice ([Fig 4E](#pone.0226440.g004){ref-type="fig"}). Form factor (FF, perimeter^2^/4π·area) was increased in cardiac tissue from tumor-bearing mice (FF 1.869 ± 0.03 in tumor-bearing mice compared to 1.687 ± 0.05 in the vehicle-injected group, p = 0.0032 ([Fig 4F](#pone.0226440.g004){ref-type="fig"}) indicating more branched mitochondria.

![Effects of LLC1 tumor cells on cardiac myofibrillar mitochondrial morphology.\
A. Ventricular tissue from PBS-injected mice (left panel) and LLC1 tumor-bearing mice (right panel). B. Average cross-sectional area (μm^2^) of intramyofibrillar mitochondria. C. Mitochondrial number per image. D. Mitochondrial density by area, calculated per image frame area of 43.588 μm^2^. E. Mitochondrial aspect ratio. F. Mitochondrial form factor (FF).](pone.0226440.g004){#pone.0226440.g004}

LLC1 tumor cell-conditioned media impairs maximal mitochondrial oxygen consumption in cultured human cardiomyocytes {#sec022}
-------------------------------------------------------------------------------------------------------------------

Since in vivo evidence points to altered mitochondrial morphology in tumor-bearing mice, we tested the effects of LLC1 tumor cell conditioned medium on cardiac mitochondrial oxygen consumption rates (OCR) in cardiomyocytes maintained in culture. Monolayers of cultured human cardiomyocytes (AC16 cells) were exposed to fresh cardiomyocyte media + 25% LLC1 tumor cell CM or LLC1 culture medium not exposed to cells (non-CM) for 24 hours prior to OCR measurements. Basal oxygen consumption rates were unchanged in AC16 cells exposed to CM or non-CM (CM OCR 9.07 ± 0.3 pmol O~2~/min/μg protein and non-CM OCR 9.19 ± 0.6 pmol O~2~/min/μg protein, p = 0.85, [Fig 5A and 5B](#pone.0226440.g005){ref-type="fig"}). After adding oligomycin, which blocks mitochondrial complex V, the OCR of both CM and non-CM treated-wells was similar ([Fig 5A](#pone.0226440.g005){ref-type="fig"}). Maximal OCR of cardiomyocytes in the presence of the uncoupling agent FCCP was significantly lower in the cells exposed to the LLC1 CM compared to the non-CM (CM OCR 12.58 ± 0.7 pmol O~2~/min/μg protein versus non-CM OCR16.67 ± 1.1 pmol O~2~/min/μg protein, p = 0.0059, [Fig 5A and 5C](#pone.0226440.g005){ref-type="fig"}). Mitochondrial reserve capacity was reduced in the cardiomyocytes exposed to CM versus non-CM (CM OCR 3.51 ± 0.8 pmol O~2~/min/μg protein and non-CM OCR 7.48 ± 0.6 pmol O~2~/min/μg protein, p = 0.0010, [Fig 5D](#pone.0226440.g005){ref-type="fig"}).

![LLC1 tumor cell conditioned medium impairs maximal and reserve mitochondrial oxygen consumption rates in cardiomyocytes.\
A. Effects of LLC1 tumor cell conditioned media (CM) and non-conditioned media (NCM) on AC16 human cardiomyocyte oxygen consumption rates, normalized to total μg protein. B. Cardiomyocyte basal respiration. C. Cardiomyocyte maximal respiration. D. Cardiomyocyte mitochondrial reserve capacity.](pone.0226440.g005){#pone.0226440.g005}

Assessment of mitochondrial OXPHOS complex proteins by immunoblot {#sec023}
-----------------------------------------------------------------

To determine whether changes in mitochondrial morphology and mitochondrial oxygen consumption induced by tumor cells, are associated with reductions in mitochondrial OXPHOS protein expression, we carried out immunoblot analysis of cardiac tissues obtained from tumor-injected or vehicle-injected mice ([Fig 6](#pone.0226440.g006){ref-type="fig"}). Complex II, III, IV and V were reduced in cardiac tissues derived from tumor-injected mice (P \< 0.0072, 0.0049, 0.029, and 0.027, respectively) compared to vehicle-injected mice.

![Effects of LLC1 tumor cells on cardiac mitochondrial OXPHOS complexes.\
A. Immunoblot of mitochondrial OXPHOS complexes derived from tumor-injected mice and vehicle-injected mice B. Densitometric analysis of complex I. C. Densitometric analysis of complex II. D. Densitometric analysis of complex IV. E. Densitometric analysis of complex III. F. Densitometric analysis of complex V. Of note, the sequence of densitometric plots corresponds to the position of the complexes on the gel.](pone.0226440.g006){#pone.0226440.g006}

Mitochondrial respiratory complex mRNA transcript levels in cardiac tissue of male tumor-bearing mice {#sec024}
-----------------------------------------------------------------------------------------------------

Mitochondrial respiratory complex mRNA transcripts were quantified by Illumina RNA-seq. Small increases (1.3 fold or lower) in the expression of mRNAs for Complex I---NADH dehydrogenase (ndufa1, ndufa3, ndufa6, ndufa7, ndufa11, ndufa13, ndufs7, ndufv1, ndufb8), Complex II---succinate dehydrogenase (sdhb), Complex III---ubiquinol-cytochrome c reductase (uqcr10, uqcr11), Complex IV---cytochrome c oxidase (cox6a2, cox8b) and Complex V---ATP synthase (atp5d) were observed in tumor-bearing mice compared to controls (FDR \< 0.05, Table A in [S1 File](#pone.0226440.s001){ref-type="supplementary-material"}).

Alterations in cardiac autophagy, proteolysis and apoptosis-related mRNA transcript levels in male tumor-bearing mice {#sec025}
---------------------------------------------------------------------------------------------------------------------

In other rodent tumor models, increased autophagy has been noted in the context of cardiac wasting \[[@pone.0226440.ref013], [@pone.0226440.ref033], [@pone.0226440.ref034]\]. To test whether an increased autophagy, proteolysis and apoptosis contribute to a decrease in cardiac wall thickness and cardiac functional impairment in LLC1 tumor-bearing male mice, we measured tissue levels of relevant transcript expression in heart tissues derived from tumor-bearing mice compared to control mice using whole transcriptome sequencing (Tables B-D in [S1 File](#pone.0226440.s001){ref-type="supplementary-material"}). Changes in some mRNA transcripts of protein influencing autophagy, proteolysis and apoptosis (FDR \< 0.05) were observed, but the fold-changes were less than 1.5-fold compared to the transcript levels in control hearts and unlikely to greatly influence cognate protein levels.

Gene expression in cardiac ventricular tissue derived from male tumor-bearing mice and control mice {#sec026}
---------------------------------------------------------------------------------------------------

To further assess changes in the expression of genes in hearts of tumor-bearing mice that could contribute to reduced cardiac wall thickness and function, we analyzed whole transcriptome data from tumor-bearing mice and control mice. We used a false discovery rate (FDR) of \<0.05 and assessed mRNAs that were changed ≤0.5-fold or ≥1.5 fold. Table E in [S1 File](#pone.0226440.s001){ref-type="supplementary-material"} shows data of the 57 transcripts that were either down-regulated or up-regulated following treatment of mice with LLC1 tumor cells. Notably, apelin (*Apl*) and apelin receptor (*Aplr*) and *N-Myc*, *Egr1* and *Sox9* mRNAs were significantly decreased. There was a greater than 2 fold increase in the expression of the mRNA for growth arrest and DNA-damage-inducible, β (*Gadd45b*) that encodes a protein involved in the regulation of growth and apoptosis.

Histological assessment of cardiac fibrosis {#sec027}
-------------------------------------------

No evidence of fibrosis was noted in cardiac tissues derived from tumor-injected mice when analyzed by hematoxylin-eosin or Masson trichrome stains (Figure A in [S1 File](#pone.0226440.s001){ref-type="supplementary-material"}) shows staining of ventricular tissue from vehicle or tumor-cell injected mice using the Masson trichrome stain).

Discussion {#sec028}
==========

Cancer incidence is predicted to increase dramatically in the coming decades\[[@pone.0226440.ref003], [@pone.0226440.ref035]\]. Patients with advanced cancer develop cachexia characterized by loss of lean and fat mass and weight loss\[[@pone.0226440.ref036], [@pone.0226440.ref037]\]. This syndrome is associated with increased morbidity and mortality, reduced response to chemotherapy and poor survival following surgery\[[@pone.0226440.ref038]--[@pone.0226440.ref041]\]. Altered regulation of inflammatory, activin A-myostatin, ubiquitin-proteasome, and autophagy-lysosomal pathways, and mitochondrial dynamics are observed in cancer-associated muscle fiber atrophy and weakness in vivo\[[@pone.0226440.ref042]--[@pone.0226440.ref049]\]. Tumor cell-derived mediators such as TNFα, IL-6, TWEAK, myostatin and extracellular vesicle HSPs have been postulated to play a role in the pathogenesis of cancer cachexia\[[@pone.0226440.ref042]--[@pone.0226440.ref045], [@pone.0226440.ref050]--[@pone.0226440.ref056]\].

Cancer cachexia involves not only skeletal muscle and fat but also involves several other organs such as the brain, liver, intestine and heart\[[@pone.0226440.ref057]\]. Reports have described cardiac involvement in patients with cancer even before the initiation of chemotherapy\[[@pone.0226440.ref004], [@pone.0226440.ref010]\]. Indeed, circulating concentrations of cardiovascular biomarker peptides like NT-proBNP, MR-proANP, MR-proADM, CT-pro-ET-1 and hsTnT are increased in an unselected population of patients with cancer prior to induction of any cardiotoxic anticancer therapy and are strongly related to all-cause mortality\[[@pone.0226440.ref010]\]. These data suggest that the presence of subclinical functional and morphological myocardial damage directly linked to disease progression.

We examined heart function by echocardiography in C57/BL6 mice following the implantation of mouse LLC1 adenocarcinoma cells. Fourteen days after LLC1 implantation, tumor-bearing male mice but not control mice, showed reduced cardiac ejection fraction, and decreased ventricular and septal wall thickness. Of note, the effects of tumor cells on cardiac function were sex-specific as female mice implanted with LLC1 cells failed to exhibit changes in cardiac function. These sex-specific effects of LLC1 tumor cells on heart function are consistent with those found by Cosper and Linewand in CD2F1 mice\[[@pone.0226440.ref020]\]. Our results showing minor effects of LLC1 cells on cardiac function in female C57BL/6 are similar to those reported by Muhlfeld et al.\[[@pone.0226440.ref058]\]. The cause for sex-related differences in tumor-induced cardiac dysfunction in our model is not known. Previous investigations have shown that the potent and specific estrogen receptor antagonist, fulvestrant, causes female tumor-bearing mice to lose as much cardiac and body mass as tumor-bearing males\[[@pone.0226440.ref020]\].

We interrogated potential pathophysiologic processes that are responsible for reduced ventricular wall thickness. We found a significant reduction in protein synthesis rates in ventricular tissue. Since tissue protein is also broken down through proteolysis following ubiquitination, we also measured the mRNA transcript levels of the E3 ubiquitin ligases, RING-finger protein-1 (MuRF1)\[[@pone.0226440.ref059]\] and F-box only protein 32 (FBXO32) protein\[[@pone.0226440.ref060]--[@pone.0226440.ref063]\] by whole transcriptome shotgun sequencing (WTSS or RNA-seq). We found minor increases in the mRNA levels of these ubiquitin ligases in heart muscle from tumor-bearing mice. Similarly mRNA transcripts for markers of autophagy, were changed to a minor extent in hearts from tumor-bearing mice\[[@pone.0226440.ref064]--[@pone.0226440.ref066]\]. Likewise, minor decreases or increases in mRNA transcripts for apoptosis-related proteins were observed. Thus, in our model of tumor-associated cardiac dysfunction, the changes in ventricular wall thickness in tumor-bearing mice are associated with a reduction in protein synthesis. Increases in protein breakdown and apoptosis are comparatively modest compared to those found in other animal models of cancer stem cell induced cardiac dysfunction. These findings of marked reductions in protein synthesis with relatively modest changes in markers of proteolysis and apoptosis are in contrast to those found in other pre-clinical models of cancer induced heart failure.

Since mitochondria provide energy for muscular contraction in heart and skeletal muscle, we assessed cardiac mitochondrial morphology as well as mitochondrial function. It is known that changes in mitochondrial morphology are associated with alterations in mitochondrial energy production\[[@pone.0226440.ref067]\]. Cardiac mitochondria from tumor-bearing mice were irregular in ventricular tissue. Measurement of the aspect ratio showed elongation of mitochondria along their longitudinal axes; form factor analysis showed increased mitochondrial branching. These changes in mitochondrial shape were not associated with changes in transcripts of fusion (*Opa1*, *Mfn 1/2*) and fission (*Fis1*, *Drp1*) mediators based on RNA-seq analysis of cardiac tissue. The data suggest that the alterations in mitochondrial shape and branching in cardiac mitochondria from tumor-bearing mice are independent of mRNA expression of fission and fusion mediators. The presence of altered mitochondrial function in the heart was confirmed in AC16 cells where an inhibitory effect of tumor CM on mitochondrial maximal oxygen uptake was noted. Further analysis of mitochondrial function was performed by immunoblot analysis of mitochondrial OXPHOS complex components where statistically significant decreases in expression of complex II-V were noted ([Fig 6](#pone.0226440.g006){ref-type="fig"}). However, analysis of the expression of mRNAs for mitochondrial respiratory chain complex components demonstrates slight increases in the expression of mRNAs for various complex components (Table A in [S1 File](#pone.0226440.s001){ref-type="supplementary-material"}). In light of the reductions in cardiac muscle protein synthesis rates, it is tempting to speculate that the transcriptional message for mitochondrial OXPHOS complex biogenesis may be blocked at the level of protein translation in the presence of LLC1 tumor burden. In aggregate, the data point to the presence of reduced mitochondrial energy production in tumor-bearing mice as a result of reduced mitochondrial oxidation. To our knowledge, previous studies have not demonstrated functional, morphological and biochemical defects in cardiac mitochondria in the context of tumor-induced heart failure.

RNA-seq analysis reveals down regulation of apelin and apelin receptor mRNAs. Apelin causes nitric oxide-dependent vasodilatation, reduces ventricular preload and afterload, and increases cardiac contractility in rats with normal and failing hearts\[[@pone.0226440.ref068], [@pone.0226440.ref069]\]. A decrease in apelin and its receptor could contribute to impaired cardiac function in the heart of tumor-bearing mice. The downregulation of the *N-Myc*, *Egr1*, *Sox9* mRNAs and the upregulation of *Gadd45b* mRNA in tumor-bearing mouse heart could conceivably be important in reducing cardiac growth and differentiation\[[@pone.0226440.ref070], [@pone.0226440.ref071]\]. The down regulation of apelin and the apelin receptor mRNA is also a novel finding and has not been reported in previous studies. It is likely to be of importance because of the reported increases in cardiac contractility induced by apelin. Finally, the down regulation of the *Egr1* may be of significant importance given the role of Egr1 in the maintenance of cellular growth.

In summary, our data show gender-specific reductions in cardiac function, ventricular wall thickness, protein synthesis, mitochondrial oxygen consumption in the presence of LLC1 tumors or conditioned media. Isolation of the factor responsible for reduced protein synthesis and oxygen consumption will yield information about factors altering cardiac function in cancer.
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======================
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Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The reviewers point out an issue with the novelty, the lack of depth of the mechanistic studies  and the unconvincing RNA-seq data. The editor concurs. Please perform further studies to provide more insightful information to address the comments as suggested.

We would appreciate receiving your revised manuscript by Nov 02 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Xiongwen Chen, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. In the Methods, please include the total number of mice used in this study.

Additional Editor Comments (if provided):

The reviewers point out an issue with the novelty, the lack of depth of the mechanistic studies and the unconvincing RNA-seq data. The editor concurs. Therefore, please address the comments with further studies as suggested.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: In this article, Dorschner et al., investigated the underlying mechanisms of cancer --induced cardiac dysfunction using a tumor-bearing mouse model. Dorschner et al. observed that male tumor-bearing mice manifest the reduced ejection fraction and ventricular wall thickness. However, this phenomena does not occur in female tumor-bearing mice. Dorschner et al. further hypothesize that reduced ventricular wall thickness and ejection fraction observed in male tumor-bearing mice could be associated with impaired protein synthesis and mitochondria function. Evidence showed that protein synthesis is reduced and mitochondria morphology and function are changed as well in male tumor-bearing mice. Dorschner et al. also performed RNA-seq and found differentially changed genes are associated with protein synthesis as well as mitochondria function. Therefore, Dorschner et al. concluded that cardiac atrophy in male tumor-bearing mice is associated with reduced protein synthesis and impaired contractile function is related to altered mitochondria function. Several comments are listed below

1\. There is no detailed discussion why authors observed cancer-induced cardiac dysfunction in male, but not in female

2\. By looking at the RNA-seq data, actually, almost all genes listed in the tables are not significantly changed (\<1.5), which is not convincing that these subtle changes are associated with cardiac dysfunction. I will suggest authors also test the protein levels with immunoblotting using hall mark genes associated with protein synthesis and mitochondria function to validate the RNA-seq data.

3\. If possible, pathological data such as fibrosis could be added which would be more supportive for the conclusion

4\. The resolution of the figures is not high.

5\. Figure 1-4 can be integrated into two figures. Characterization of male mice can be consolidated into figure 1, and female data in figure 2

6\. In figure 5, authors used over 9 animals in B and C, but why only 4 animals were used in A?

7\. I would suggest moving the tables with next generation sequencing data to supplement.

Reviewer \#2: In the present manuscript, Kumar and colleagues aimed to address pathological changes in the heart under tumor-bearing conditions. The authors utilized lung tumor as an example to induce cachexia and evaluated heart function. They showed, in a convincing way, cardiomyopathy emerged at 14 days post tumor inoculation. Moreover, the heart growth was impaired. The authors went further to show mitochondria had certain abnormalities and maximal oxygen consumption was reduced.

1\. The studies were thoughtfully designed and nicely executed. However, the conclusions suffer from questions in novelty. Tumor-related cachexia and related heart disease has been noted for years. Moreover, previous studies have suggested the increase in atrophy and decrease in mitochondrial action may contribute. For a few examples, please see, Spring H, 2014, EHJ; Tian M, 2010, International J of Oncology, etc. Therefore, the present study may not provide significant conceptual advances in the field of cachexia-associated heart disorder.

2\. In the last figure, conditioned media (CM) from tumor cells inhibited OCR. Is this due to inflammatory cytokines? If so, how to narrow down the candidates?

3\. The authors have done thorough analysis for the RNA-Seq data. What about changes at the protein level? Such as atrophy-related proteins and the growth signaling pathway (i.e. mTOR).

4\. The authors may need to compare the ratio of heart weight/tibia length, since body weight may be affected by tumor.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0226440.r002

Author response to Decision Letter 0

27 Sep 2019

Response to reviewers.

ALL CHANGES HAVE BEEN UNDERLINED IN THE REVISED MANUSCRIPT.

Reviewer \#1:

Summary of findings: In this article the authors investigated the underlying mechanisms of cancer-induced cardiac dysfunction using a tumor-bearing mouse model. They observed that male tumor-bearing mice manifest the reduced ejection fraction and ventricular wall thickness. However, these phenomena do not occur in female tumor-bearing mice. They further hypothesize that reduced ventricular wall thickness and ejection fraction observed in male tumor-bearing mice could be associated with impaired protein synthesis and mitochondria function. Evidence showed that protein synthesis is reduced and mitochondria morphology and function are changed as well in male tumor-bearing mice. The authors also performed RNA-seq and found differentially changed genes are associated with protein synthesis as well as mitochondria function. Therefore, they concluded that cardiac atrophy in male tumor-bearing mice is associated with reduced protein synthesis and impaired contractile function is related to altered mitochondria function. Several comments are listed below:

Comments and responses:

Comment 1. There is no detailed discussion why authors observed cancer-induced cardiac dysfunction in male, but not in female.

Response: We discuss why female mice do not respond in a manner similar to male mice. Previous work (Cosper PF, Leinwand LA. Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner. Cancer Res. 2011;71(5):1710-20) has shown that this is mediated by the estrogen receptor. The use of an estrogen receptor blocking agent, fulvestrant, in female mice with cancer, is associated with a response that is similar to that observed in male mice. We have now added text discussing this issue.

Comment 2. By looking at the RNA-seq data, actually, almost all genes listed in the tables are not significantly changed (\<1.5), which is not convincing that these subtle changes are associated with cardiac dysfunction. I will suggest authors also test the protein levels with immunoblotting using hall mark genes associated with protein synthesis and mitochondria function to validate the RNA-seq data.

Response: We now provide immunoblot data showing that changes in the mRNAs for components of the mitochondrial respiratory chain complex are paralleled by changes observed in protein components of the respiratory chain complex assessed by (new figure 6).

Comment 3. If possible, pathological data such as fibrosis could be added which would be more supportive for the conclusion

Response: We examined cardiac tissues by histology and did not notice an increase in fibrosis. A statement to this effect is now included in the manuscript.

Comment 4. The resolution of the figures is not high.

Response: This has now been corrected.

Comment 5. Figure 1-4 can be integrated into two figures. Characterization of male mice can be consolidated into figure 1, and female data in figure 2

Response: This has now been done.

Comment 6. In figure 5, authors used over 9 animals in B and C, but why only 4 animals were used in A?

Response: We had only 4 samples available to us for analysis of 13C phenylalanine incorporation into protein.

Comment 7. I would suggest moving the tables with next generation sequencing data to supplement.

Response: We have moved the next generation sequencing data into the supplement.

Reviewer \#2

Summary of findings: In the present manuscript, Kumar and colleagues aimed to address pathological changes in the heart under tumor-bearing conditions. The authors utilized lung tumor as an example to induce cachexia and evaluated heart function. They showed, in a convincing way, cardiomyopathy emerged at 14 days post tumor inoculation. Moreover, the heart growth was impaired. The authors went further to show mitochondria had certain abnormalities and maximal oxygen consumption was reduced.

Comment 1. The studies were thoughtfully designed and nicely executed. However, the conclusions suffer from questions in novelty. Tumor-related cachexia and related heart disease has been noted for years. Moreover, previous studies have suggested the increase in atrophy and decrease in mitochondrial action may contribute. For a few examples, please see, Spring H, 2014, EHJ; Tian M, 2010, International J of Oncology, etc. Therefore, the present study may not provide significant conceptual advances in the field of cachexia-associated heart disorder.

Response: Previous studies have demonstrated heart failure in various animal models injected with different types of tumor cells. Our study, however, significantly adds to knowledge about mechanisms responsible for reduced cardiac function. First, to our knowledge, we are unaware of studies performed previously with LLC1 cells, a model of lung non-small cell tumors. Second, we are unaware of studies in which investigators have examined the effect of tumor conditioned medium on mitochondrial oxygen uptake and the effect of tumor cell implantation on cardiac protein synthesis. Third, using whole transcriptome sequencing, we show reductions in the expression of mRNAs which encode proteins that affect cardiac function and growth e.g. Apelin, Apelin receptor, Sox 9, and Egr1. Increases in the expression of mRNAs involved in the regulation of growth arrest and apoptosis such as Gadd45B is noted in tumor-bearing mice.

Comment 2. In the last figure, conditioned media (CM) from tumor cells inhibited OCR. Is this due to inflammatory cytokines? If so, how to narrow down the candidates?

Response: We thank the reviewer for the comment. We do not know the mediator for a reduction in mitochondrial oxygen consumption rate. This is an ongoing project in our laboratory at the present time. We have added text to address this issue and potential paths that can be taken to isolate such a mediator.

Comment 3. The authors have done thorough analysis for the RNA-Seq data. What about changes at the protein level? Such as atrophy-related proteins and the growth signaling pathway (i.e. mTOR).

Response: Please see the response to comment 2 by reviewer 1. We now provide data showing that changes in the mRNAs for components of the mitochondrial respiratory chain complex are paralleled by changes observed in components of the respiratory chain complex assessed by Western blotting (new figure 6).

Comment 4. The authors may need to compare the ratio of heart weight/tibia length, since body weight may be affected by tumor.

Response: We thank the reviewer for the comment. Unfortunately, animal carcasses are no longer available for us to make this determination.

###### 

Submitted filename: Response to reviewers.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0226440.r003

Decision Letter 1

Chen

Xiongwen

Academic Editor

© 2019 Xiongwen Chen

2019

Xiongwen Chen

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

8 Nov 2019

PONE-D-19-19216R1

Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice

PLOS ONE

Dear Dr. Kumar,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

These two external reviewers are satisfied with your revision and only a minor addition of evidence of fibrosis is requested. Please revise accordingly and the revised version will expedited for acceptance.

We would appreciate receiving your revised manuscript by Dec 23 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Xiongwen Chen, PhD

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have adequately addressed my concerns. I appreciate that the authors added the statement of cardiac fibrosis, even though the authors didn\'t observe any significant difference, I would suggest the authors add the figure evidence to the supplement.

Reviewer \#2: I want to thank the authors for addressing my concerns on technical issues. While I agree with the authors that this study provides certain novel insights about this type of tumor cells in triggering heart disease, the authors may consider to discuss previous findings in a manner of comparing with the current work.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0226440.r004

Author response to Decision Letter 1

13 Nov 2019

RESPONSE TO REVIEWERS.

ALL CHANGES HAVE BEEN HIGHLIGHTED IN YELLOW IN THE REVISED MANUSCRIPT.

Reviewer \#1:

Comments and responses:

Comment 1. The authors have a adequately addressed my concerns. I appreciate that the author is added the statement of cardiac fibrosis, even though the author is did not observe any significant difference, I would suggest the author is added the figure evidence to the supplement.

Response: We have now added of figure (Supplemental Figure 1) showing the absence of fibrosis in cardiac tissue derived from tumor-implanted mice using the Masson Trichrome which is exceptionally sensitive for sensitive for fibrosis. As noted, we did not observe fibrosis in either the vehicle or tumor cell injected mice.

Reviewer \#2

Comment 1. I want to thank the authors for addressing my concerns on technical issues. While I agree with the authors that this study provides certain novel insights about this type of tumor cells in triggering heart disease, the authors may consider discussing previous findings in a matter of comparing with current work

Response: Thank you for your comments. We have added sentences now in which we discuss our work in comparison to work previously published by others.

###### 

Submitted filename: Response to reviewers 11-11-2019.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0226440.r005
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© 2019 Xiongwen Chen

2019

Xiongwen Chen

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

27 Nov 2019

Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice

PONE-D-19-19216R2

Dear Dr. Kumar,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Xiongwen Chen, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have addressed all my questions and I have No further concerns.

Reviewer \#2: No further revision is needed. All questions have been satisfactorily addressed. I want to thank the authors for addressing the concerns.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

10.1371/journal.pone.0226440.r006

Acceptance letter

Chen

Xiongwen

Academic Editor

© 2019 Xiongwen Chen

2019

Xiongwen Chen

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

10 Dec 2019

PONE-D-19-19216R2

Impaired cardiac performance, protein synthesis, and mitochondrial function in tumor-bearing mice

Dear Dr. Kumar:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr Xiongwen Chen

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
